Latest news with #H22025
Yahoo
07-07-2025
- Business
- Yahoo
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the best hot stocks to buy according to Wall Street analysts. In the middle of June, Citius Oncology, which is an oncology-focused subsidiary of Citius Pharmaceuticals, announced that it is nearing completion of preparations for the commercial launch of LYMPHIR. LYMPHIR is an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma/CTCL, indicated for Stage I-III disease after at least one prior systemic therapy. The company anticipates a US launch of LYMPHIR in H2 2025. Citius Oncology has completed commercial-scale manufacturing of LYMPHIR, with sufficient packaged and labeled inventory to meet projected demand for 12 to 18 months post-launch. The product supports a shelf life of 60 months. To facilitate broad access and timely delivery across the US, Citius Oncology has executed one and is finalizing other distribution services agreements with multiple top-tier global pharmaceutical logistics partners. An experienced physician performing a procedure using specialty pharmaceutical products. The commercial team has developed a targeted launch strategy using a proprietary GenAI model to identify and engage key accounts. A suite of marketing and educational materials, such as clinical guides, dosing protocols, and disease awareness content, has been developed for providers, patients, and caregivers. LYMPHIR's inclusion in the National Comprehensive Cancer Network/NCCN Clinical Practice Guidelines, along with the assignment of a permanent J-code under HCPCS and ongoing engagement with payors, positions the product for efficient reimbursement and coverage upon launch. Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is a biopharmaceutical company that develops and commercializes critical care products. While we acknowledge the potential of CTXR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Times of Oman
05-07-2025
- Business
- Times of Oman
Gold prices likely to trend higher in second half of 2025, may touch Rs 1 lakh: Report
New Delhi: Local gold prices in the country are expected to maintain an upside bias in the second half of 2025, potentially moving from the current range of Rs 96,500-Rs 98,500 per 10 grams toward the psychologically significant Rs 1,00,000 mark, according to a report by ICICI Bank Global Markets. Contrary to the global trend, domestic gold prices grew by 0.6 per cent in June, driven by a mild INR depreciation of 0.2 per cent. "Local gold prices are expected to continue trading with an upside bias moving from a near-term range of Rs 96,500 to Rs 98,500 per ten grams to Rs 98,500 per ten grams to the Rs 100,000 per ten grams range in H22025," the report added. In volume terms, gold imports have fallen on a sequential basis, showing that demand is weakening in response to elevated prices. Gold imports of USD 2.5bn were recorded in May compared to USD 3.1bn in the previous month. Investment demand was strong in May. Data released by the AMFI showed a net ETF inflow of Rs 2.92 billion in May, after two consecutive months of outflows, highlighting the robust investment-related demand for the yellow metal in the local markets. On the global front, despite the sequential fall in gold prices, investment demand for the yellow metal remained strong, which is evident from ETF flows as well. The SPDR ETF flows in gold increased from 930 tonnes as of 1st June 2025 to 948 tonnes as of 1st July 2025. At the same time, speculative net long positions rose by roughly 13k lots in the last month. In recent months, the gold bull run appears to have stalled as prices have been flat over the last month, reflecting an easing in safe-haven demand that has taken place, even as they remain higher on a YTD basis in 2025 by 28 per cent. A critical development was the ceasefire reached between Israel and Iran that improved risk sentiment and reduced demand for the yellow metal. At the same time, markets are positioning for the US government to agree on trade deals with other countries that will limit the need for reciprocal tariffs to be implemented, the report added. The US has already agreed deals with the UK and Vietnam, while there has been considerable progress made in negotiations with other countries such as Japan, India and the EU. Besides, the US and China have agreed upon a framework for a trade deal as well that will be concluded presumably by August. "The upshot is that the easing in geopolitical tensions and expectations that trade-war 2.0 could ease in magnitude have worked to limit further sharp upside emerging in gold prices," the report added.
Yahoo
05-07-2025
- Business
- Yahoo
Valaris Sells Jackup Rig VALARIS 247 for $108M, Boosts Financial Flexibility
Valaris Limited (NYSE:VAL) is one of the best up and coming stocks to invest in now. Earlier in May, Valaris announced its agreement to sell the jackup rig VALARIS 247 to BW Energy/BWE for ~$108 million in cash. The sale is anticipated to finalize in H2 2025, pending standard closing conditions. Under this agreement, BWE will be restricted from deploying the rig for operations outside of BWE-owned or affiliated properties for the remainder of its useful life. The VALARIS 247 is a 27-year-old jackup rig that is currently operating offshore Australia. A closeup of an offshore oil rig in the international oil and gas industry in the Gulf of Mexico. The President and CEO of the company, Anton Dibowitz, said that the company is pleased to announce this opportunistic transaction to sell VALARIS 247, as upon the sale's completion, the proceeds will enhance Valaris's financial flexibility. Valaris Limited (NYSE:VAL) provides offshore contract drilling services internationally through four segments: Floaters, Jackups, ARO, and Other. While we acknowledge the potential of VAL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target
Atai Life Sciences (NASDAQ:ATAI) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 6, analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Atai Life Sciences (NASDAQ:ATAI), retaining the price target of $6.00. The analyst gave the optimistic rating due to various factors, including the strategic merger between Beckley Psytech and Atai Life Sciences (NASDAQ:ATAI). A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. Expected to close in H2 2025, the merger is expected to strengthen Atai Life Sciences' (NASDAQ:ATAI) pipeline through Beckley's advanced short-acting psychedelic programs, including BPL-003. The merger is, however, contingent upon the success of the Phase 2b trial for BPL-003 in treatment-resistant depression, with results expected to be released by mid-2025. The analyst further reasoned that Atai Life Sciences' (NASDAQ:ATAI) financial position is further bolstered by the concurrent $30 million private placement, which is independent of the merger. The company also has a robust pipeline, such as its internal VLS-01 DMT program, which, according to Okunewitch, can provide potential benefits in the psychedelic therapy market. Headquartered in Germany, Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on treating mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
